Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography

Stein, 2000, Multidisciplinary approach to esophageal and gastric cancer, Surg Clin North Am, 80, 659, 10.1016/S0039-6109(05)70205-X

Medical Research Council Oesophageal Cancer Working Group, 2002, Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial, Lancet, 359, 1727, 10.1016/S0140-6736(02)08651-8

Kelsen, 1998, Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer, N Engl J Med, 339, 1979, 10.1056/NEJM199812313392704

Bosset, 1997, Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus, N Engl J Med, 337, 161, 10.1056/NEJM199707173370304

Urba, 2001, Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma, J Clin Oncol, 19, 305, 10.1200/JCO.2001.19.2.305

Gebski, 2007, Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis, Lancet Oncol, 8, 226, 10.1016/S1470-2045(07)70039-6

Korst, 2006, Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma, Ann Thorac Surg, 82, 480, 10.1016/j.athoracsur.2006.03.072

Ancona, 2001, Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone, Cancer, 91, 2165, 10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO;2-H

Donington, 2003, Tumor response to induction chemoradiation: influence on survival after esophagectomy, Eur J Cardiothorac Surg, 24, 631, 10.1016/S1010-7940(03)00397-X

Whiting, 2003, The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews, BMC Med Res Methodol, 3, 25, 10.1186/1471-2288-3-25

Walter, 2002, Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data, Stat Med, 21, 1237, 10.1002/sim.1099

Rosman, 2007, Application of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testing, Adv Med Sci, 52, 76

Zamora, 2006, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data, BMC Med Res Methodol, 6, 31, 10.1186/1471-2288-6-31

Hirata, 1997, Using endosonography to assess the effects of neoadjuvant therapy in patients with advanced esophageal cancer, AJR Am J Roentgenol, 169, 485, 10.2214/ajr.169.2.9242759

Giovannini, 1997, Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer, Endoscopy, 29, 4, 10.1055/s-2007-1004053

Willis, 2002, Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma, Gastrointest Endosc, 55, 655, 10.1067/mge.2002.123273

Kroep, 2003, Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods, Mol Imaging Biol, 5, 337, 10.1016/j.mibio.2003.09.007

Swisher, 2004, Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer, Ann Thorac Surg, 78, 1152, 10.1016/j.athoracsur.2004.04.046

Cerfolio, 2005, The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy, J Thorac Cardiovasc Surg, 129, 1232, 10.1016/j.jtcvs.2004.12.042

Ota, 2005, Useful endoscopic ultrasonography to assess the efficacy of neoadjuvant therapy for advanced esophageal carcinoma: based on the response evaluation criteria in solid tumors, Dig Endosc, 17, 59, 10.1111/j.1443-1661.2005.00458.x

Brucher, 2001, Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography, Ann Surg, 233, 300, 10.1097/00000658-200103000-00002

Flamen, 2002, Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer, Ann Oncol, 13, 361, 10.1093/annonc/mdf081

Wieder, 2004, Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment, J Clin Oncol, 22, 900, 10.1200/JCO.2004.07.122

Song, 2005, FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer, Int J Radiat Oncol Biol Phys, 63, 1053, 10.1016/j.ijrobp.2005.03.033

Bruzzi, 2007, Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy, Cancer, 109, 125, 10.1002/cncr.22397

Gillham, 2006, 18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response, Br J Cancer, 95, 1174, 10.1038/sj.bjc.6603412

Levine, 2006, Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer, Ann Surg, 243, 472, 10.1097/01.sla.0000208430.07050.61

Ott, 2006, Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction, J Clin Oncol, 24, 4692, 10.1200/JCO.2006.06.7801

Westerterp, 2006, Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET, Int J Hyperthermia, 22, 149, 10.1080/02656730500513523

Lordick, 2007, PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial, Lancet Oncol, 8, 797, 10.1016/S1470-2045(07)70244-9

Mamede, 2007, FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results, J Clin Oncol, 30, 377, 10.1097/COC.0b013e31803993f8

Port, 2007, Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma, Ann Thorac Surg, 84, 393, 10.1016/j.athoracsur.2007.03.094

Mandard, 1994, Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations, Cancer, 73, 2680, 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Weber, 2008, Technology insight: advances in molecular imaging and an appraisal of PET/CT scanning, Nat Clin Pract Oncol, 5, 160, 10.1038/ncponc1041

Flamen, 2004, Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer, Q J Nucl Med Mol Imaging, 48, 96

Weber, 2001, Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging, J Clin Oncol, 19, 3058, 10.1200/JCO.2001.19.12.3058

Westerterp, 2005, Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review, Radiology, 236, 841, 10.1148/radiol.2363041042

Das, 2006, Reassessment of patients with esophageal cancer after neoadjuvant therapy, Endoscopy, 38, S13, 10.1055/s-2006-946644